2017 Multidisciplinary Thoracic Cancers Symposium
Douglas E. Wood, MD, on Lung Cancer Screening
Douglas E. Wood, MD, of the University of Washington, discusses the importance of broad access to and education about lung cancer screening—now approved for people at high risk for the disease—and the...
Charles B. Simone, II, MD, on NSCLC: CTCs as a Biomarker for Early Detection
Charles B. Simone, II, MD, of the University of Maryland Medical Center, discusses results from a large prospective study in locally advanced non–small cell lung cancer, which suggest that circulating...
Boris Sepesi, MD, on NSCLC, TILs, and Overall Survival
Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center, discusses immune cells within tumors and the potential role for checkpoint inhibitor therapy in the neoadjuvant setting of local...
Zofia Piotrowska, MD, on NSCLC: Resistance Mechanisms
Zofia Piotrowska, MD, of the Massachusetts General Hospital Cancer Center, discusses heterogeneity and variation in resistance mechanisms among EGFR-mutant non–small cell lung cancer patients with at ...
Zhongxing Liao, MD, on Proton-Beam Radiotherapy for Locally Advanced Disease
Zhongxing Liao, MD, of The University of Texas MD Anderson Cancer Center, discusses the continued improvement in planning, delivery, and patient selection for proton therapy, which can both reduce rad...
Jennifer Ho, MD, on Thoracic Cancers: Reirradiation With IMPT
Jennifer Ho, MD, of The University of Texas MD Anderson Cancer, discusses study results on the use of intensity-modulated proton therapy, which can provide durable local control with minimal toxicity ...
Tracey L. Evans, MD, on NSCLC: Combined-Modality Therapy
Tracey L. Evans, MD, of the University of Pennsylvania, discusses the data supporting use of chemotherapy with radiation in locally advanced non–small cell lung cancer, targeted treatments and immunot...
Martin J. Edelman, MD, on NSCLC: Final Results of a CALGB Alliance Trial
Martin J. Edelman, MD, of Fox Chase Cancer Center, discusses study findings from a phase III study of celecoxib in addition to standard chemotherapy for advanced non–small cell lung cancer with COX-2 ...
Maximilian Diehn, MD, PhD, on Liquid Biopsies/Cell-Free DNA: Clinical Uses
Maximilian Diehn, MD, PhD, of Stanford School of Medicine, discusses promising clinical applications of circulating tumor DNA in patients with thoracic malignancies: noninvasive detection of resistanc...
Shraddha M. Dalwadi, MBA, on Stage I NSCLC: Racial Disparities in Treatment and Outcome
Shraddha M. Dalwadi, MBA, MD Candidate in the class of 2017 at Texas A&M Health Science Center, discusses findings from a SEER database study that showed African Americans and American Indians wit...
Richard J. Cassidy III, MD, on NSCLC and SBRT in Older Patients
Richard J. Cassidy III, MD, of Emory Winship Cancer Institute, discusses results from a multicenter analysis of stereotactic body radiotherapy for early-stage non-small cell lung cancer in patients 80...
Kamran Ahmed, MD, on Lung Cancer, Radiation, and Immune Checkpoint Inhibitors
Kamran Ahmed, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses results from a small study of pneumonitis in patients who received thoracic radiotherapy within 6 months of anti...
